Pharmacokinetic bioequivalence of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using a handheld syringe or an on-body delivery system
This study demonstrated the feasibility of a hands-free device approach to deliver pertuzumab and trastuzumab in one fixed-dose combination for subcutaneous injection without compromising pharmacokinetics and safety.
Authors
- Rong Deng (ORCID: https://orcid.org/0000-0003-2005-7517)
- Junyi Li (ORCID: https://orcid.org/0000-0003-3847-3527)
- Fabiola Bene Tchaleu
- Daniel Eiger (ORCID: https://orcid.org/0000-0002-9879-6048)
- Eleonora Restuccia (ORCID: https://orcid.org/0000-0001-5751-094X)
- Sarah Heeson
- Bei Wang (ORCID: https://orcid.org/0000-0002-9530-0385)
- Chris Wynne
Institutions
- Roche (Switzerland) (CH)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1007/s00432-025-06228-4
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- F. Hoffmann-La Roche
- Genentech